International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder

被引：96

作者：

Crunelle, Cleo L. ^{[1
,2
]}

van den Brink, Wim ^{[3
]}

Moggi, Franz ^{[4
]}

Konstenius, Maija ^{[5
]}

Franck, Johan ^{[5
]}

Levin, Frances R. ^{[6
]}

van de Glind, Geurt ^{[7
]}

Demetrovics, Zsolt ^{[8
]}

Coetzee, Corne ^{[9
]}

Luderer, Mathias ^{[10
]}

Schellekens, Arnt ^{[11
]}

Matthys, Frieda ^{[1
]}

机构：

[1] Univ Ziekenhuis Brussel UZ Brussel, Vrije Univ Brussel, Dept Psychiat, Brussels, Belgium

[2] Antwerp Univ, Toxicol Ctr, Antwerp, Belgium

[3] Univ Amsterdam, Acad Med Ctr, AIAR, Amsterdam, Netherlands

[4] Univ Bern, Univ Hosp Psychiat, Bern, Switzerland

[5] Karolinska Inst, Stockholm, Sweden

[6] Columbia Univ, New York State Psychiat Inst, New York, NY USA

[7] Univ Amsterdam, ICASA Fdn, Amsterdam, Netherlands

[8] Eotvos Lorand Univ, Budapest, Hungary

[9] Univ Limpopo, Dept Pharm, Sovenga, South Africa

[10] Heidelberg Univ, Dept Addict Behav & Addict Med, Cent Inst Mental Hlth, Med Fac Mannheim, Heidelberg, Germany

[11] Radboudumc, Dept Psychiat, Donders Inst Brain Cognit & Behav, NISPA, Nijmegen, Netherlands

来源：

EUROPEAN ADDICTION RESEARCH | 2018年 / 24卷 / 01期

关键词：

Attention deficit/hyperactivity disorder; Substance use disorders; Diagnosis; Treatment; Consensus; DEFICIT HYPERACTIVITY DISORDER; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; SELF-REPORT SCALE; ADULT ADHD; TREATMENT-SEEKING; DOUBLE-BLIND; NONMEDICAL USE; METHYLPHENIDATE;

D O I：

10.1159/000487767

中图分类号：

R194 [卫生标准、卫生检查、医药管理];

学科分类号：

摘要：

Adult attention deficit/hyperactivity disorder (ADHD) often co-occurs with substance use disorders (SUD) and is associated with early onset and more severe development of SUD and with reduced treatment effectiveness. Screening tools allow for a good recognition of possible ADHD in adults with SUD and should be used routinely, followed by an ADHD diagnostic process initiated as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. This paper includes evidence- and consensus-based recommendations developed to provide guidance in the screening, diagnosis and treatment of patients with ADHD-SUD comorbidity. (c) 2018 S. Karger AG, Basel

引用

页码：43 / 51

页数：9

共 50 条

[11] Clinical practice guideline on pharmacological and psychological management of adult patients with attention deficit and hyperactivity disorder and comorbid substance use
Cunill, Ruth
Castells, Xavier
Gonzalez-Pinto, Ana
Arrojo, Manuel
Bernardo, Miquel
Saiz, Pilar A.
Florez, Gerardo
Torrens, Marta
Tirado-Munoz, Judit
Fonseca, Francia
Arranz, Belen
Garriga, Marina
Manuel Goikolea, Jose
Zorrilla, Inaki
Becona, Elisardo
Lopez, Ana
San, Luis
ADICCIONES, 2022, 34 (02) : 168 - 178
[12] Managing Adult Attention-deficit/Hyperactivity Disorder With Comorbid Substance Use Disorder
Ward, Burton
Bahji, Anees
Crockford, David
CANADIAN JOURNAL OF ADDICTION, 2022, 13 (04) : 6 - 12
[13] The Complicated Relationship Between Attention Deficit/Hyperactivity Disorder and Substance Use Disorders
Zulauf, Courtney A.
Sprich, Susan E.
Safren, Steven A.
Wilens, Timothy E.
CURRENT PSYCHIATRY REPORTS, 2014, 16 (03)
[14] Randomized, Controlled Trial of Atomoxetine for Attention-Deficit/Hyperactivity Disorder in Adolescents With Substance Use Disorder
Thurstone, Christian
Riggs, Paula D.
Salomonsen-Sautel, Stacy
Mikulich-Gilbertson, Susan K.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2010, 49 (06) : 573 - 582
[15] Differences in alcohol and cannabis use amongst substance use disorder patients with and without comorbid attention-deficit/hyperactivity disorder
Coetzee, Corne
Truter, Ilse
Meyer, Anneke
SOUTH AFRICAN JOURNAL OF PSYCHIATRY, 2022, 28
[16] Methylphenidate doses in Attention Deficit/Hyperactivity Disorder and comorbid substance use disorders
Skoglund, Charlotte
Brandt, Lena
D'Onofrio, Brian
Larsson, Henrik
Franck, Johan
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 (11) : 1144 - 1152
[17] Attention deficit hyperactivity disorder and substance misuse: an evaluation of causal hypotheses and treatment considerations
Young, Susan
Sedgwick, Ottilie
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (09) : 1005 - 1014
[18] Expert consensus statement for telepsychiatry and attention-deficit hyperactivity disorder
Hong, Jennifer
Mattingly, Gregory W.
Carbray, Julie A.
Cooper, Takesha V.
Findling, Robert L.
Gignac, Martin
Glaser, Paul E.
Lopez, Frank A.
Maletic, Vladamir
McIntyre, Roger S.
Robb, Adelaide S.
Singh, Manpreet K.
Stein, Mark A.
Stahl, Stephen M.
CNS SPECTRUMS, 2024, 29 (05) : 451 - 462
[19] Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder
Robinson, Christopher L.
Parker, Katelyn
Kataria, Saurabh
Downs, Evan
Supra, Rajesh
Kaye, Alan D.
Viswanath, Omar
Urits, Ivan
HEALTH PSYCHOLOGY RESEARCH, 2022, 10 (03):
[20] Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence
Cunill, R.
Castells, X.
Tobias, A.
Capella, D.
JOURNAL OF PSYCHOPHARMACOLOGY, 2015, 29 (01) : 15 - 23

← 1 2 3 4 5 →